Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Cytotoxicity of Anthrax Lethal Toxin to Human Acute Myeloid Leukemia Cells Is Nonapoptotic and Dependent on Extracellular Signal-Regulated Kinase 1/2 Activity. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2012 · External reference
The myelodysplastic syndromes: morphology, risk assessment, and clinical management
10.1007/bf03165122 · 2002 · External reference
Specificity and mechanism of action of some commonly used protein kinase inhibitors
1999 · External reference
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase
10.1073/pnas.052707699 · 2002 · External reference
Braf status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin
10.1158/1535-7163.mct-05-0145 · 2005 · External reference
V599EB-Raf is an oncogene in melanocytes
10.1158/0008-5472.can-03-3433 · 2004 · External reference
The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia
10.1038/sj.leu.2402460 · 2002 · External reference
The Ras-Raf-MEK-ERK pathway in the treatment of cancer
2002 · External reference
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis
10.1158/0008-5472.can-04-0866 · 2004 · External reference
Therapeutic targeting of the Mek/Mapk signal transduction module in acute myeloid leukemia
10.1172/jci12807 · 2001 · External reference
Identification of the cellular receptor for anthrax toxin
10.1038/n35101999 · 2001 · External reference
Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor
10.1073/pnas.0431098100 · 2003 · External reference
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process
10.1083/jcb.200211018 · 2003 · External reference
Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis
10.1083/jcb.200507067 · 2006 · External reference
A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformation
10.1073/pnas.0604000103 · 2006 · External reference
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor
10.1126/science.280.5364.734 · 1998 · External reference
Anthrax lethal factor proteolysis and inactivation of MAPK kinase
10.1074/jbc.m211262200 · 2003 · External reference
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice
10.1158/1078-0432.ccr-06-2019 · 2006 · External reference
Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network
10.1158/0008-5472.can-09-1567 · 2009 · External reference
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies
10.1007/s00109-012-0886-z · 2012 · External reference
The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells
10.1038/sj.leu.2403828 · 2005 · External reference
Production, recovery and immunogenicity of the protective antigen from a recombinant strain of Bacillus anthracis
10.1038/sj.jim.7000239 · 2002 · External reference
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin
10.1074/jbc.m011085200 · 2001 · External reference
The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells
10.1016/s0145-2126(02)00077-2 · 2003 · External reference
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry
2006 · External reference
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
10.1158/1078-0432.ccr-11-2381 · 2012 · External reference
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation
10.1016/j.jss.2011.10.045 · 2012 · External reference
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
10.1038/bjc.2012.70 · 2012 · External reference
Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer
10.1158/1535-7163.mct-12-0098 · 2012 · External reference
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
10.1158/0008-5472.can-08-4765 · 2009 · External reference
An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia
10.1038/sj.thj.6200327 · 2003 · External reference
Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
10.1182/blood.v99.9.3461 · 2002 · External reference
Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling
10.1182/blood.v97.6.1823 · 2001 · External reference
